Saturday, October 31, 2026

USD/CHF Edges Higher, Ignores Bearish Bets On US Dollar Ahead Of US PMI, Fed Decision: (USDCHF) Over 3% Down In The Last 21 Sessions

Via News Just in

July 24, 2023

USD/CHF Edges Higher, Ignores Bearish Bets On US Dollar Ahead Of US PMI, Fed Decision: (USDCHF) Over 3% Down In The Last 21 Sessions
(VIANEWS) - USD/CHF clings to mild gains around 0.8665 as markets brace for the top-tier data/events during early Monday in Europe. That said, the Swiss Franc (CHF) pair rose for the first time in four weeks, bouncing off the lowest levels since late 2015, as the US Dollar cheered upbeat data to challenge the dovish Fed bias. However, the recently bearish US Dollar bias of the asset managers and anxiety ahead of today's preliminary readings of the US S&P Global PMIs for July challenge the pair buyers of late. FXStreet reported on the fact that that said, Bloomberg quotes the US Commodity Futures Trading Commission (CFTC) data for the week ended on July 18 to state that asset managers boosted bearish dollar bets to a record 18% amid speculation slowing US inflation will hasten the end of the Federal Reserve's 16-month run of policy tightening. USD/CHF (USDCHF) has been up by 3.29% for the last 21 sessions. At 06:08 EST on Monday, 24 July, USD/CHF (USDCHF) is $0.87.

Usd/chf oscillates in a range just above mid-0.8600s, upside potential seems limited

The US Dollar (USD) manages to preserve its recent recovery gains from its lowest level since April 2022 touched last week and turns out to be a key factor acting as a tailwind for the USD/CHF pair. , The outlook, in turn, will play a key role in influencing the near-term USD price dynamics and help investors to determine the next leg of a directional move for the USD/CHF pair.

Usd/chf edges higher past 0.8650, ignores bearish bets on US dollar ahead of US pmi, fed decision

Hence, the USD/CHF pair traders will not only pay attention to today's US PMIs but will also closely observe the first readings of the US second-quarter (Q2) 2023 Gross Domestic Product (GDP) and Fed Chair Jerome Powell's ability to defend the hawks for clear directions. , The first daily closing beyond the 10-DMA in two weeks keeps USD/CHF buyers hopeful unless the drops back below the DMA resistance-turned-support of 0.8642. USD/CHF's yearly highs and lows, it's 1.11% up from its 52-week low and 14.704% down from its 52-week high.

Volatility

USD/CHF's last week, last month's, and last quarter's current intraday variation average was a positive 0.13%, a negative 0.14%, and a positive 0.39%, respectively. USD/CHF's highest amplitude of average volatility was 0.40% (last week), 0.40% (last month), and 0.39% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CHF's Forex is considered to be oversold (<=20). More news about USD/CHF (USDCHF).
Via News Just in

Breaking news and real-time updates on financial markets, business developments, and economic events from Via News.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com